| 0.5495 -0.08 (-12.72%) | 12-08 12:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.78 |
1-year : | 1.01 |
| Resists | First : | 0.67 |
Second : | 0.87 |
| Pivot price | 0.46  |
|||
| Supports | First : | 0.34 |
Second : | 0.29 |
| MAs | MA(5) : | 0.58 |
MA(20) : | 0.46 |
| MA(100) : | 0.64 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.3 |
D(3) : | 52 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 3.2 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VRAX ] has closed below upper band by 31.1%. Bollinger Bands are 111.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.65 | 0.65 - 0.65 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.62 - 0.63 | 0.63 - 0.64 |
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Thu, 04 Dec 2025
Virax Biolabs Secures $5 Million in Private Placement to Advance Immunology Research - TipRanks
Thu, 04 Dec 2025
Virax Biolabs (Nasdaq: VRAX) closes $5 million raise, cash runway into 2028 - Stock Titan
Thu, 04 Dec 2025
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PR Newswire
Thu, 04 Dec 2025
Virax Biolabs Unveils $5 Million Private Placement - Nasdaq
Thu, 04 Dec 2025
Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally - Benzinga
Wed, 03 Dec 2025
Virax Biolabs Group Limited Announces $5 Million Private Placement - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.68e+006 (%) |
| Held by Institutions | 8.2 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.91e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -238 % |
| Return on Assets (ttm) | 316.8 % |
| Return on Equity (ttm) | -64.7 % |
| Qtrly Rev. Growth | 6330 % |
| Gross Profit (p.s.) | -60.68 |
| Sales Per Share | -70.67 |
| EBITDA (p.s.) | -32759.3 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.67 |
| Dividend | 0 |
| Forward Dividend | 21530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|